TNT Sports Johnson Reveals Diagnosis of Follicular Lymphoma
US TNT television host Ernie Johnson revealed Wednesday that a swollen lymph node under his ear is the result of a follicular non-hodgkin's lymphoma.
Johnson says "Two and a half years ago, in August of 2003, I was diagnosed with follicular Non-Hodgkin's Lymphoma. This is a low-grade and treatable cancer -- not as aggressive as some other forms...The only reason I'm bringing my condition to your attention now is because the swelling of a lymph node near my left ear has become noticeable to viewers of TNT and there have been questions asked."
Johnson will continue to work throughout the rest of the NBA basketball regular season and playoffs and will likely undergo chemotherapy treatment in June. He's been with Turner Sports for 16 years. He currently hosts TNT's NBA and PGA golf coverage as well as TBS' Pac-10 and Big-12 college football broadcasts.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
